Navigation Links
Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Detroit As Part Of Educational Initiative
Date:6/26/2012

DETROIT, June 26, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications for Novo Nordisk Community Care Detroit, a community-based initiative that supports local programs that educate people living with type 2 diabetes.  The sponsorships are part of the Novo Nordisk Community Care program, which aims to promote sustainable change by working with locally based nonprofit groups in cities across the country to help communities most affected address the growing diabetes crisis.  Novo Nordisk will invest $80,000 as part of the initiative to support organizations in Detroit.  For more information and to download an application form, interested organizations should visit www.NovoNordisk-US.com/CommunityCare

"More than 1.1 million Michigan residents were faced with diabetes in 2010," said Lori Moore, Executive Director of Communications and Public Affairs at Novo Nordisk.  "As an industry leader, Novo Nordisk is committed to reversing the trend of the diabetes crisis.  We recognize that community-based organizations play a critical role in providing diabetes education and care that can help defeat this disease."

In 2011, Novo Nordisk Community Care sponsored more than 20 diverse community-based programs and awarded $415,000 to organizations in Atlanta, Minneapolis, Boston, and Philadelphia.  Last year's sponsored programs were selected for their unique content focused on education and resources for patients, ranging from interactive workshops, material for underserved and minority populations, and faith-based community initiatives.  This year, Novo Nordisk will offer new sponsorship opportunities to eligible nonprofit organizations dedicated to educating and empowering patients in Detroit to become more engaged in their health and management of type 2 diabetes. 

Diabetes has become a global health crisis, and is taking a major toll on our communities, with Detroit bearing a large part of the burden.  A recent model from the Institute for Alternative Futures (IAF), commissioned by Novo Nordisk, estimates that the number of Americans living with diabetes will increase 64% between 2010 and 2025, affecting more than 53 million people.  And, in Michigan, it's estimated that the number of people with diabetes will increase 42% between 2010 and 2025, affecting more than 1.6 million people, including 703,000 people in Detroit.  This dramatic increase could mean a total of $15.8 billion in total medical and indirect societal costs of diabetes for the state of Michigan in 2025.  

If not properly managed, diabetes can lead to other serious health issues such as heart disease, stroke, kidney disease, blindness, amputation, and other complications.

About Novo Nordisk

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
2. invivodata President Selected as Finalist for Ernst & Young Entrepreneur of the Year Award
3. picoSpin-45 Benchtop NMR Spectrometer a Finalist in the European Life Sciences Awards
4. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
5. Exotic Automation & Supply Receives Ford’s 2011 World Excellence Award
6. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
7. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
8. Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
9. The Scientist Magazine’s 2012 Multimedia Awards—Call for Entries
10. Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs
11. 2011-2012 Michael E. DeBakey Journalism Award Winners Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... ... August 11, 2020 , ... ... chain validation engineering firm, is making available for free its new white ... incorporate concurrent transport simulation testing into today’s biologics licensing application (BLA). In ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... that they have entered into a strategic partnership whereby Catalent will provide support ...
Breaking Biology Technology:
(Date:7/10/2020)... ... 2020 , ... Today CJ BIO announced the first in a series of ... taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a ... July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
(Date:6/25/2020)... , ... June 24, 2020 , ... ... enterprise software and software-driven clinical data services that accelerate drug development, is collaborating ... selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the ...
Breaking Biology News(10 mins):